https://www.pharmaradar360.com/article/6867a9881ffb4123PharmaRadar360en2026-04-04T00:00:00.000ZNeoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort studyhttps://www.pharmaradar360.com/article/0f435b1fa5d01fe9PharmaRadar360en2026-04-03T16:40:38.000ZUpdate on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesityhttps://www.pharmaradar360.com/article/804ab4c4b8e5c4bcPharmaRadar360en2026-04-03T16:39:26.000ZFDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopausehttps://www.pharmaradar360.com/article/b61516ae705d3db3PharmaRadar360en2026-04-03T16:38:04.000ZFDA adds Boxed Warning about a rare but serious allergic reaction called anaphylaxis with the multiple sclerosis medicine glatiramer acetate (Copaxone, Glatopa)https://www.pharmaradar360.com/article/a404d444d2011d8bPharmaRadar360en2026-04-03T16:37:21.000ZFDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)https://www.pharmaradar360.com/article/728effda035abf2ePharmaRadar360en2026-04-03T16:34:30.000ZFDA adds warning about serious risk of heat-related complications with antinausea patch Transderm Scōp (scopolamine transdermal system)https://www.pharmaradar360.com/article/1fd9b354a64af8f6PharmaRadar360en2026-04-03T16:22:47.000ZFDA is requiring opioid pain medicine manufacturers to update prescribing information regarding long-term usehttps://www.pharmaradar360.com/article/509da04ce09736d3PharmaRadar360en2026-04-03T16:21:59.000ZFDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapinehttps://www.pharmaradar360.com/article/3c3e82bc6cb61f4aPharmaRadar360en2026-04-03T16:20:38.000ZWhat’s New for Biologicshttps://www.pharmaradar360.com/article/0cb4a9273df8b292PharmaRadar360en2026-04-03T16:19:54.000ZFDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab)https://www.pharmaradar360.com/article/df707750700308f5PharmaRadar360en2026-04-03T16:19:18.000ZFDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medicationshttps://www.pharmaradar360.com/article/c52a0f1915d8ee77PharmaRadar360en2026-04-03T16:18:42.000ZFDA Is Requiring Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products Containing Carbidopa/Levodopahttps://www.pharmaradar360.com/article/75ccb73b41c103f8PharmaRadar360en2026-04-03T16:17:49.000ZFDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan) for Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitishttps://www.pharmaradar360.com/article/f089159bf084a00dPharmaRadar360en2026-04-03T16:14:42.000ZGeneric Drug User Fee Amendmentshttps://www.pharmaradar360.com/article/526ea48a30db7604PharmaRadar360en2026-04-03T15:35:08.000ZAs They Grow: Teaching Your Children How To Use Medicines Safelyhttps://www.pharmaradar360.com/article/8b52f918f614601aPharmaRadar360en2026-04-03T15:17:01.000ZFDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)https://www.pharmaradar360.com/article/b10fdd6b1624327bPharmaRadar360en2026-04-03T15:15:40.000ZStop - Learn - Go: Tips for Talking with Your Pharmacist to Learn How to Use Medicines Safelyhttps://www.pharmaradar360.com/article/665b9552c1f8a205PharmaRadar360en2026-04-03T15:11:15.000ZFDA Rare Disease Innovation Hub